Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.
The world of sequence variation IP is complicated and confusing, and fraught with legal risk, but there is a solution, as Ellen Sherin of GQ Life Sciences reports.
Since joining Eli Lilly’s patent division nearly 20 years ago, Manisha Desai has worked on the procurement and enforcement of patents worldwide.
A shift in Mexico’s examination practice on plant-related patents has caused legal uncertainty, say Daniel Eduardo López and Esteban Rodríguez of Clarke Modet & Co.
A lack of blood donors and poor healthcare infrastructure inspired Temie Giwa-Tubosun to develop and deliver a life-saving app. LSIPR spoke to the founder of LifeBank.
Marie-Paule Kieny of the Drugs for Neglected Diseases Initiative is on a mission to remind stakeholders and governments that there is a moral imperative to pursue the fight against neglected diseases, as she tells LSIPR.
A team at the University of Dundee has announced a major breakthrough in the understanding of Parkinson’s disease. LSIPR heard more from Miratul Muqit and Daan van Aalten of the university’s school of life sciences.
Glenda Gray, CEO and president of the South African Medical Research Council, tells LSIPR of the life-saving work she is undertaking and her ambitious goals to improve the South African healthcare landscape.
Balancing a company’s duty to shareholders with the public responsibility to provide lifesaving treatments is a constant challenge, as Issi Rozen, chief business officer at the Broad Institute of MIT and Harvard, tells LSIPR.
With his interests in IP development, biotechnology innovation policy, and R&D, Luiz Otávio Pimentel, president of Brazil’s patent office, tells LSIPR of his aims to improve the country’s IP performance.